Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP286323.RAApyCncu_hmSYLi7A2udxVd40wZF3a_5mt7mEwnz0IdA130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP286323.RAApyCncu_hmSYLi7A2udxVd40wZF3a_5mt7mEwnz0IdA130_assertion type Assertion NP286323.RAApyCncu_hmSYLi7A2udxVd40wZF3a_5mt7mEwnz0IdA130_head.
- NP286323.RAApyCncu_hmSYLi7A2udxVd40wZF3a_5mt7mEwnz0IdA130_assertion description "[The incidence of TET2, ASXL1, CBL, IDH or IKZF1 mutations in these disorders ranges from 0 to 17%; these latter mutations are more common in chronic (TET2, ASXL1, CBL) or juvenile (CBL) myelomonocytic leukemias, mastocytosis (TET2), myelodysplastic syndromes (TET2, ASXL1) and secondary acute myeloid leukemia, including blast-phase MPN (IDH, ASXL1, IKZF1).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP286323.RAApyCncu_hmSYLi7A2udxVd40wZF3a_5mt7mEwnz0IdA130_provenance.
- NP286323.RAApyCncu_hmSYLi7A2udxVd40wZF3a_5mt7mEwnz0IdA130_assertion evidence source_evidence_literature NP286323.RAApyCncu_hmSYLi7A2udxVd40wZF3a_5mt7mEwnz0IdA130_provenance.
- NP286323.RAApyCncu_hmSYLi7A2udxVd40wZF3a_5mt7mEwnz0IdA130_assertion SIO_000772 20428194 NP286323.RAApyCncu_hmSYLi7A2udxVd40wZF3a_5mt7mEwnz0IdA130_provenance.
- NP286323.RAApyCncu_hmSYLi7A2udxVd40wZF3a_5mt7mEwnz0IdA130_assertion wasDerivedFrom befree-20150227 NP286323.RAApyCncu_hmSYLi7A2udxVd40wZF3a_5mt7mEwnz0IdA130_provenance.
- NP286323.RAApyCncu_hmSYLi7A2udxVd40wZF3a_5mt7mEwnz0IdA130_assertion wasGeneratedBy ECO_0000203 NP286323.RAApyCncu_hmSYLi7A2udxVd40wZF3a_5mt7mEwnz0IdA130_provenance.